Synexus Clinical Research GmbH

At Synexus Clinical Research GmbH in Berlin, investigators are studying Chronic Obstructive Pulmonary Disease (COPD) to evaluate new therapies that may lower the frequency of moderate and severe exacerbations and improve patients’ daily functioning.

• Efficacy of novel anti‑inflammatory agents
• Reduction of COPD exacerbation rates
• Long‑term safety of inhaled treatment options

The research aims to provide clearer evidence for clinicians, while offering participants access to potentially more effective care options.

The Berlin site is also conducting trials in the field of metabolic health, focusing on obesity and related cardiovascular risk. One study examines the safety profile of survodutide in individuals who are overweight or obese, seeking to demonstrate non‑inferior cardiovascular outcomes compared with standard care.

• Weight management and lifestyle integration
• Cardiovascular outcome assessment in metabolic disorders
• Non‑inferiority evaluation of emerging metabolic agents

By addressing both weight reduction and heart health, the trials aim to expand therapeutic options for patients struggling with metabolic disease.